ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Pharmacology of medications used for ovarian stimulation
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 129817" data-attributes="member: 13851"><p><strong>Practice Points </strong></p><p></p><p> The mechanisms of action of medications used to stimulate the ovaries are based on the physiology of the hypothalamic-pituitary-ovarian axis </p><p></p><p> Common ovulatory disorders include hypothalamic anovulation, polycystic ovary syndrome and ovarian insufficiency/hypergonadotropic anovulation </p><p></p><p> Whenever possible attempts should be made to treat the underlying ovarian disorder, such as hypothyroidism or a prolactin-secreting lactotroph adenoma </p><p></p><p> The ideal treatment for WHO I anovulation (hypothalamic amenorrhea) is pulsatile GnRH, administered via a subcutaneous pump (available in Europe but not the United States) </p><p></p><p> The aromatase inhibitor Letrozole is superior to Clomiphene for ovulation induction in polycystic ovary syndrome, and now considered the first line therapy </p><p></p><p> The gonadotropins LH and FSH, derived from menopausal urine or recombinant, are used for ovulation induction or as part of controlled ovarian hyperstimulation (COH) as part of assisted reproductive technology (ART) cycles</p><p></p><p> FSH alone can produce follicular maturation, but patients with hypothalamic dysfunction require LH, and outcomes of COH in ART may be superior with mixed preparations</p><p></p><p> Glucocorticoids, androgens and Coenzyme Q10 may be used as adjuvants for ovarian stimulation but lack proven efficacy. </p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Research Agenda </strong></p><p></p><p> The hypothalamic KISS1 system has emerged as a major target for future research into ovarian stimulation and the treatment of reproductive disorders </p><p></p><p> The role of androgens in ovarian stimulation for poor responders requires further investigation </p><p></p><p> Co-Enzyme Q10 is a mitochondrial nutrient that may improve outcomes of ovarian stimulation; clinical trials are ongoing</p><p></p><p> Long-acting FSH preparations may replace daily FSH injections as part of COH in the future</p><p></p><p> The search for orally active gonadotropin agonists is ongoing, but has thus far been unsuccessful </p><p></p><p> Oral GnRH antagonists such as Elagolix are being investigated in the treatment of endometriosis-associated pain and leiomyomyas, and may become part of stimulation protocols in ART in the future </p><p></p><p> Pharmacogenomics research may assist in the choice of ovarian stimulation in ART in the future.</p></blockquote><p></p>
[QUOTE="madman, post: 129817, member: 13851"] [B]Practice Points [/B] The mechanisms of action of medications used to stimulate the ovaries are based on the physiology of the hypothalamic-pituitary-ovarian axis Common ovulatory disorders include hypothalamic anovulation, polycystic ovary syndrome and ovarian insufficiency/hypergonadotropic anovulation Whenever possible attempts should be made to treat the underlying ovarian disorder, such as hypothyroidism or a prolactin-secreting lactotroph adenoma The ideal treatment for WHO I anovulation (hypothalamic amenorrhea) is pulsatile GnRH, administered via a subcutaneous pump (available in Europe but not the United States) The aromatase inhibitor Letrozole is superior to Clomiphene for ovulation induction in polycystic ovary syndrome, and now considered the first line therapy The gonadotropins LH and FSH, derived from menopausal urine or recombinant, are used for ovulation induction or as part of controlled ovarian hyperstimulation (COH) as part of assisted reproductive technology (ART) cycles FSH alone can produce follicular maturation, but patients with hypothalamic dysfunction require LH, and outcomes of COH in ART may be superior with mixed preparations Glucocorticoids, androgens and Coenzyme Q10 may be used as adjuvants for ovarian stimulation but lack proven efficacy. [B]Research Agenda [/B] The hypothalamic KISS1 system has emerged as a major target for future research into ovarian stimulation and the treatment of reproductive disorders The role of androgens in ovarian stimulation for poor responders requires further investigation Co-Enzyme Q10 is a mitochondrial nutrient that may improve outcomes of ovarian stimulation; clinical trials are ongoing Long-acting FSH preparations may replace daily FSH injections as part of COH in the future The search for orally active gonadotropin agonists is ongoing, but has thus far been unsuccessful Oral GnRH antagonists such as Elagolix are being investigated in the treatment of endometriosis-associated pain and leiomyomyas, and may become part of stimulation protocols in ART in the future Pharmacogenomics research may assist in the choice of ovarian stimulation in ART in the future. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Pharmacology of medications used for ovarian stimulation
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top